Posted by Michael Wonder on 13 Nov 2018
ICR responds to NICE decision on olaparib for women with advanced ovarian cancer
9 November 2018 - NICE has announced today its decision not to recommend olaparib for women with advanced ovarian cancer who had previously responded to platinum chemotherapy for six months or longer.
Responding to the decision, Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
“Today’s decision is a disappointing one for women with advanced ovarian cancer and their doctors. We would like to see olaparib available on the NHS for a broader group of women, to provide them with an important new treatment option.
